Phase 1/2a, Multi-center, Open-Label, Dose-escalating Study to Assess Safety, Tolerability, and Pharmacokinetics of Intravenously Administered IPL344 for The Treatment of Amyotrophic Lateral Sclerosis (ALS)
Phase of Trial: Phase I/II
Latest Information Update: 20 Feb 2019
At a glance
- Drugs IPL-344 (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors Immunity Pharma
- 05 Sep 2018 New trial record
- 14 Aug 2018 According to an Immunity Pharma media release, phase 2b portion could be the basis for a conditional regulatory approval of the drug for the benefit of ALS patients.
- 14 Aug 2018 According to an Immunity Pharma media release, the first report of the trial outcomes is expected in mid-2019.